[go: up one dir, main page]

MX2019005349A - Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos. - Google Patents

Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos.

Info

Publication number
MX2019005349A
MX2019005349A MX2019005349A MX2019005349A MX2019005349A MX 2019005349 A MX2019005349 A MX 2019005349A MX 2019005349 A MX2019005349 A MX 2019005349A MX 2019005349 A MX2019005349 A MX 2019005349A MX 2019005349 A MX2019005349 A MX 2019005349A
Authority
MX
Mexico
Prior art keywords
anticancer compounds
sanglifehrin macrocyclic
macrocyclic analogues
analogues
sanglifehrin
Prior art date
Application number
MX2019005349A
Other languages
English (en)
Inventor
James Moss Steven
Alan Gregory Matthew
GRÖNBERG Alvar
Joakim Hansson Magnus
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Publication of MX2019005349A publication Critical patent/MX2019005349A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a los usos de los análogos de sangliferina macrocíclicos en el tratamiento del cáncer, especialmente cáncer de hígado.
MX2019005349A 2016-11-18 2017-11-17 Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos. MX2019005349A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670920 2016-11-18
DKPA201770054 2017-01-30
PCT/EP2017/079549 WO2018091634A1 (en) 2016-11-18 2017-11-17 Use of sanglifehrin macrocyclic analogues as anticancer compounds

Publications (1)

Publication Number Publication Date
MX2019005349A true MX2019005349A (es) 2019-08-05

Family

ID=62146196

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005349A MX2019005349A (es) 2016-11-18 2017-11-17 Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos.

Country Status (10)

Country Link
US (1) US10857150B2 (es)
EP (1) EP3541388A1 (es)
JP (1) JP2019535726A (es)
KR (1) KR20190077476A (es)
CN (1) CN110062626A (es)
AU (1) AU2017361856A1 (es)
BR (1) BR112019009903A2 (es)
CA (1) CA3043131A1 (es)
MX (1) MX2019005349A (es)
WO (1) WO2018091634A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
IL320513A (en) 2019-11-04 2025-06-01 Revolution Medicines Inc RAS inhibitors
CR20220240A (es) * 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
US11608346B2 (en) * 2019-11-04 2023-03-21 Revolution Medicines, Inc. Ras inhibitors
WO2021142115A1 (en) * 2020-01-09 2021-07-15 President And Fellows Of Harvard College Sanglifehrin analogs and uses thereof
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
CN112870198A (zh) * 2020-12-31 2021-06-01 长安医院有限公司 芦可替尼在制备治疗慢粒继发骨髓纤维化药物中的应用
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
IL322109A (en) 2023-02-14 2025-09-01 Hoffmann La Roche Tricyclic compounds for cancer treatment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4475916A (en) 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
WO2011098808A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098809A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
GB201008123D0 (en) 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
CA3028414C (en) 2010-12-20 2021-01-26 Neurovive Pharmaceutical Ab Sanglifehrin derivatives and methods for their production
JO3063B1 (ar) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
GB201118334D0 (en) * 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form

Also Published As

Publication number Publication date
EP3541388A1 (en) 2019-09-25
CN110062626A (zh) 2019-07-26
JP2019535726A (ja) 2019-12-12
CA3043131A1 (en) 2018-05-24
BR112019009903A2 (pt) 2019-08-13
US20190328734A1 (en) 2019-10-31
WO2018091634A1 (en) 2018-05-24
AU2017361856A1 (en) 2019-05-23
US10857150B2 (en) 2020-12-08
KR20190077476A (ko) 2019-07-03

Similar Documents

Publication Publication Date Title
MX2019005349A (es) Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos.
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
ZA202004557B (en) Modulatory polynucleotides
SA520411108B1 (ar) مركبات حلقية كبيرة واستخداماتها
MX2023010042A (es) Polinucleotidos moduladores.
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
MX2019003938A (es) Compuestos espirociclicos.
TN2017000183A1 (en) Macrocyclic peptides useful as immunomodulators
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
PH12019502002A1 (en) Combination theraphy
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
PH12014502032A1 (en) Treatment of brain cancer
PH12016501422A1 (en) Functionalised benzopyran compounds and use thereof
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
MX379622B (es) Compuestos espirociclicos
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2017014436A (es) Compuestos biciclicos.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
WO2016130581A8 (en) Combination cancer therapy
MX2016009056A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
PH12016501838A1 (en) Compounds and their methods of use
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer